Inhibition of the renin-angiotensin system after acute myocardial infarction - treat first, select later?

Heart

Volumn 76, Issue 3 SUPPL. 3, 1996, Pages 73-78

  Hall, Alistair S ^a   Sapsford, Rob ^a   Megarry, Simon G ^a   Ball, Stephen G ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; RAMIPRIL;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HYPOTENSION; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0029904070     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.76.3_suppl_3.73     Document Type: Review

References (31)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316: 1429-35.
2. Collins R, Julian D. British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. Br Heart J 1991;66: 250 5.
3. De Vita C, Franzosi MG, Geraci E, Maggioni AP, Mauri F, Mezzanotte G, et al. GISSI-2: mortality plus extensive left-ventricular damage as "end-point" (letter). Lancet 1990;335:289.
4. Hall AS, Tan LB, Ball SG. Inhibition of ACK/kininase-II, acute myocardial infarction, and survival. Cardiovasc Res 1994;28:190 8.
5. Hutchins GM, Bulkley BH. Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 1978;41:1127 32.
6. ISIS-4 Collaborative Group. Fourth International Study of Infarct Survival (ISIS-4): a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345: 669 85.
7. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancer 1994;343:1115 22.
8. Ambrosioni E, Borghi C, Magnani B. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
9. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
10. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678 84.
11. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, et al. The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669 77.
12. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821 8.
13. The Trace Study Group. The Trandolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. Am J Cardiol 1994;73:44 50C.
14. The Trace Study Group. Oral presentation at World Congress of Cardiology, Berlin, 1994.
15. Latini R, Maggioni AP, Zuanetti G, Franzosi MG, Tognoni G on behalf of the GISSE-3 investigators. ACE inhibitors post-MI: the case for early, nonselective treatment. Controversies in Cardiology 1995;6:9 12.
16. Furberg CD, Yusuf S. Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol 1985;55: 1110 3.
17. van Gilst WH, de Graeff PA, Kingma JH, Wesseling H, de Langen CD. Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion Eur J Pharmacol 1984;100:113 7.
18. de Graeff PA, van Gilst WH, de Langen CD, Kingma JH, Wesseling H. Concentration-dependent protection by captopril against ischacmia-reperfusion injury in the isolated rat heart. Arch Int Pharmacodyn Ther 1986;280: 181-93.
19. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection tractions and congestive heart failure. N Engl J Med 1991;325: 293 302.
20. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published erratum appears in N Engl J Med 1992;327:1768]. N Engl J Med 1992;327:685 91.
21. Furberg CD, Campbell RW, Pitt B. ACE-inhibitors after myocardial infarction [letter]. N Engl J Med 1993;328: 967 9.
22. Ganley CJ, Hung HM, Temple R. More on the survival and ventricular enlargement trial [letter; comment]. N Engl J Med 1993;329:1204-6.
23. GISSI-3 Investigators. Oral presentation at World Congress of Cardiology, Berlin, 1994.
24. Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 1988;319:80 6.
25. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72:406 12.
26. Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988;i:255 9.
27. Hall AS. Clinical trials versus actual practice. In: Ball SG, ed. Myocardial infarction: from trials to practice. Petersfield, UK: Wrightson Biomedical Publishing Ltd, 1995.
28. Tognoni G. On behalf of the Gruppo Itahano per lo Studio della Sopravvivenza nell'Infarcto Micardico [letter]. Lancet 1994;343:1633 4.
29. Hall AS, Ball SG. Update on the use of ACE-inhibition therapy after acute myocardial infarction. Exp Opin Invest Drugs 1995;4:143 6.
30. Weisman HF, Healy B. Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis 1987;30:73 110.
31. Hall AS, Ball SG. Clinical background to the use of ACK-inhibitor therapy after myocardial infarction. J Cardiovascular Risk 1995;2:396 405.